Results for
""Furans""[mesh_terms]

Marine plant-based biorefinery for sustainable 2,5-furandicarboxylic acid production: A review.

Chung-Han Chung, Yong-Suk Lee, Jae Bok Heo

Bioresource technology 2023;390():129817

Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis.

Kaniz Afroz Tanni, Cong Bang Truong, Jingjing Qian, Brandon S Johnson

Critical reviews in oncology/hematology 2021;163():103375

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer.

C Tian, Q Ouyang, Z-Y Hu, Z Shui, M Cao, X Hu, J Gao, J Lu, H Wu, X Yang, H Xiao, J Li, N Xie, J Ran, L Liu, B Liu

ESMO open 2023;8(3):101563

Ambrafuran (Ambrox) Synthesis from Natural Plant Product Precursors.

Ian A Dubery, Lucia Steenkamp, Efficient N Ncube

Molecules (Basel, Switzerland) 2021;25(17):3851

A comprehensive review of furan in foods: From dietary exposures and in vivo metabolism to mitigation measures.

Yu Zhang, Yiju Zhang

Comprehensive reviews in food science and food safety 2023;22(2):809-841

Eribulin: Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects.

Prescrire international 2012;21(124):37-8

Identification of a sotolon pathway in dry white wines.

Denis Dubourdieu, Philippe Darriet, Yannick Landais, Valérie Lavigne, Alexandre Pons

Journal of agricultural and food chemistry 2010;58(12):7273-9

Relative importance and interactions of furan precursors in sterilised, vegetable-based food systems.

Biniam T Kebede, Ann Van Loey, Marc E Hendrickx, Peter Goos, Koen Vanratingen, Carolien Buvé, Tara Grauwet, Stijn Palmers

Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment 2016;33(2):193-206

Domino syntheses of bioactive tetronic and tetramic acids.

Rainer Schobert

Die Naturwissenschaften 2008;94(1):1-11

Eribulin mesylate for the treatment of breast cancer.

Tessa Cigler, Linda T Vahdat

Expert opinion on pharmacotherapy 2010;11(9):1587-93

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Javier Cortes, Alberto J Montero, Stefan Glück

Cancer treatment reviews 2012;38(2):143-51

The karrikin 'calisthenics': Can compounds derived from smoke help in stress tolerance?

Aryadeep Roychoudhury, Durgesh Kumar Tripathi, Aditya Banerjee

Physiologia plantarum 2019;165(2):290-302

Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.

Jeong Eun Kim, Inkyung Jung, Hyo Song Kim, Jin-Hee Ahn, Sun Young Rha, Su-Jin Shin, Yoon Woo Koh, Jee Hung Kim, Sang Kyum Kim, Yoon Dae Han, Wooyeol Baek, Seung Hyun Kim, Young Han Lee, Kum-Hee Yun, Nam Suk Sim, Chang Gon Kim

Clinical cancer research : an official journal of the American Association for Cancer Research 2022;28(15):3225-3234

Analysis of the solvent strength parameter (linear solvent strength model) for isocratic separations in reversed-phase liquid chromatography.

Sanka N Atapattu, Colin F Poole

Journal of chromatography. A 2022;1675():463153

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Kazuki Sudo, Noboru Yamamoto, Taro Semba, Kohei Yamaguchi, Shuya Takashima, Yohei Otake, Keisuke Yasuda, Daiko Matsuoka, Satoshi Shiono, Kohei Shitara, Kan Yonemori, Shunsuke Kondo, Satoru Iwasa, Yuki Katsuya, Shu Yazaki, Yoshiaki Nakamura, Makoto Nishino, Hanae Ida, Toshio Shimizu, Jun Sato, Takafumi Koyama, Takao Takase, Takuya Suzuki

Cancer research communications 2023;3(7):1189-1199